Aagya Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 1.00 M
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 29.00 Cr
- Revenue Growth -9.97%
- Profit Growth -8.35%
- Ebitda -0.07%
- Net Worth 24.52%
- Total Assets -0.05%
About Aagya Biotech
Aagya Biotech Private Limited (ABPL) is a Private Limited Indian Non-Government Company incorporated in India on 29 July 2016 (Eight years and six months 26 days old ). Its registered office is in Haridwar, Uttarakhand, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹29.00 Cr.
Aditya Arora and Archit Arora serve as directors at the Company.
Company Details
- Location
Haridwar, Uttarakhand, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999UR2016PTC007216
- Company No.
007216
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jul 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Who are the key members and board of directors at Aagya Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Archit Arora  | Director | 29-Jul-2016 | Current |
| Aditya Arora | Director | 29-Jul-2016 | Current |
Financial Performance of Aagya Biotech.
Aagya Biotech Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 9.97% decrease. The company also saw a slight decrease in profitability, with a 8.35% decrease in profit. The company's net worth Soared by an impressive increase of 24.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aagya Biotech?
In 2021, Aagya Biotech had a promoter holding of 10.00% and a public holding of 90.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹29.00 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 29.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Dec 2023 | Others | ₹4.00 Cr | Open |
| 30 Mar 2021 | Others | ₹25.00 Cr | Open |
How Many Employees Work at Aagya Biotech?
Aagya Biotech has a workforce of 358 employees as of Feb 10, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aagya Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aagya Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.